San Diego, California, United States
• Identified and advanced multiple small molecules to clinical development. • Expertise in the use of state-of-the-art drug design techniques and tools, including Structure-Based Drug Design; Spotfire data and drug properties analysis. • Extensive hands-on knowledge in hit triage, lead optimization to IND. · Advanced understanding of drug Pharmacokinetics; Dynamics; Metabolisms and Toxicities. · Working experience in AI and ML training for drug discovery. • Experienced in polymer synthesis, purification and analysis through dialysis, GPC and SEC. • Experienced in project management and supervision of a multidisciplinary group of Research Scientists and Research Associates. • A project leader and supervisor for internal and external scientists (CROs). Specialties: structure based drug design, property based drug design, hit triage, lead optimization, small molecule and polymer synthesis, CRO management.
Train LLM to improve performance accuracy on drug discovery domain.
Evaluate AI and ML output, as pertaining to drug discovery. Use medicinal chemistry and DMPK principals to enhance model performance.
Jump start small molecule program(s) with designs and guidance for hit generation, hit to lead, lead optimization and beyond. Approaches include DEL, LBDD, SBDD, FBDD, covalent inhibitors and PROTAC.
Led the medicinal chemistry effort to target the RNA binding proteins with small molecules, for oncology and immunology therapies. Identified and together with the team, advanced a key program compound to the development candidate.
Led a team of more than twenty chemists, including both internal and external, to identify small molecules for antibacterial therapies. Identified hits/leads via SBDD. Identified and advanced the key asset (FG-2101) from hit/lead to clinical development.
Medicinal chemistry/drug discovery